Cerus vs PROCEPT BioRobotics
CERS and PRCT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CERS and PRCT compare
PROCEPT BioRobotics is the larger company, worth 3.1 times as much as Cerus ($1.3B against $427M).
Cerus keeps more of each dollar of sales as profit, with a net margin of −2.9% compared with −32.6% at PROCEPT BioRobotics.
PROCEPT BioRobotics scores higher on the StockData Score (9 against 6 for Cerus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CERS | PRCT |
|---|---|---|
| Size and price | ||
| Market cap | $427M | $1.3B |
| Share price | $2.12 | $23.34 |
| Change, 1 year | 32.5% | −24.6% |
| Change, 5 years | −70.6% | −42.6% |
| Beta (5Y) | 1.72 | 1.30 |
| Employees | 275 | 888 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 2 | 2 |
| Growth score | 0 | 3 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 3.8× |
| P/B | 5.6× | 4.1× (better) |
| P/FCF | 865× | – |
| FCF yield | 0.12% (better) | −6.4% |
| Fair value | $2.72 | $48.08 |
| Margin of safety | 22.1% | 51.5% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 17.5% |
| Revenue growth, 5Y average | 15.4% | 109% (better) |
| Profitability | ||
| Gross margin | – | 64.7% |
| Operating margin | −0.97% (better) | −33.6% |
| Net margin | −2.9% (better) | −32.6% |
| FCF margin | 0.19% (better) | −24.1% |
| Return on equity | −10.7% (better) | −32.4% |
| Return on invested capital | −966% | −62.4% (better) |
| Financial health | ||
| Debt / equity | – | 0.16 |
| Interest coverage | −0.4× (better) | −34.7× |
| Current ratio | 1.96 | 5.89 (better) |
| Altman Z-score | −3.78 | 4.18 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.01% | – |
| Shareholder yield | 0.01% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 74.8% | 95.8% |
| Held by insiders | 6.0% | 4.8% |
| Insider net buying, 12 months | −$3.2M | $10.3M (better) |
| Short interest, % of float | 7.7% | 14.4% |
Go deeper
- CERS stock overview
- CERS income statement
- CERS valuation and score
- PRCT stock overview
- PRCT income statement
- PRCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.